Bridging the valley of death: a conversation with Thomas Cueni about the AMR Fund
Q&A on the AMR Fund with Thomas Cueni, director general of IFPMA
The International Federation of Pharmaceutical Manufacturers & Associations has spearheaded the creation of the AMR Action Fund, which has lined up about $1 billion from over 20 pharmas to invest in biotechs developing solutions to antimicrobial resistance.
BioCentury spoke with IFPMA Director General Thomas Cueni, who called the fund a bridge that will carry a few products from Phase II to approval. Cueni noted that other “push” mechanisms are in place for antibiotic development, including the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the REPAIR Impact Fund, which was established by Novo Holdings, but these initiatives focus on early-stage development.
Cueni stressed that the fund is only part of